Outcome Measures for Clinical Trials in Fragile X Syndrome
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Progress in basic neuroscience has led to identification of molecular targets for treatment in fragile X syndrome (FXS) and other neurodevelopmental disorders; however, there is a gap in translation to targeted therapies in humans. One major obstacle to the demonstration of efficacy in human trials has been the lack of generally accepted endpoints to assess improvement in function in individuals with FXS. To address this problem, the National Institutes of Health convened a meeting of leading scientists and clinicians with the goal of identifying and standardizing outcome measures for use as potential endpoints in clinical trials in FXS. METHODS: Participants in the meeting included FXS experts, experts in the design and implementation of clinical trials and measure development, and representatives from advocacy groups, industry, and federal agencies. RESULTS: The group generated recommendations for optimal outcome measures in cognitive, behavioral, and biomarker/medical domains, including additional testing and validation of existing measures and development of new measures in areas of need. Although no one endpoint or set of endpoints could be identified that met all criteria as an optimal measure, recommendations are presented in this report. CONCLUSION: The report is expected to guide the selection of measures in clinical trials and lead to the use of a more consistent battery of measures across trials. Furthermore, this will help to direct research toward gaps in the development of validated FXS-specific outcome measures and to assist with interpretation of clinical trial data by creating templates for measurement of treatment efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 2×
“This research should strive to identify and develop measures that (1) are psychometrically sound with high reliability, validity, and sensitivity to change for the FXS population; (2) index core features of the FXS phenotype, at the neurobiological level or the level of cognition, emotion, and behavior; (3) focus on c…”
BackgroundTEST REVIEW behavior rating inventory of executive function.
Gioia, G. A., Isquith, P. K., Guy, S. C., & Kenworthy, L. (2000) · Child Neuropsychology · doi:10.1076/chin.6.3.235.3152 · Cited by 1,925
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Varieties of Repetitive Behavior in Autism: Comparisons to Mental Retardation
Bodfish, J. W., Symons, F. J., Parker, D. E., & Lewis, M. H. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005596502855 · Cited by 1,223
SWANSON, J. M., KRAEMER, H. C., HINSHAW, S. P., ARNOLD, L. E., CONNERS, C. K., ABIKOFF, H. B., CLEVENGER, W., DAVIES, M., ELLIOTT, G. R., GREENHILL, L. L., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00011 · Cited by 1,157
Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function
Bassell, G. J., & Warren, S. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.004 · Cited by 1,051 · cited 4×
“This recommendation led to a successful 5-site collaborative study of the psychometric properties of the ABC in more than 600 individuals with FXS91 and utilization in clinical trials.25,27 The working group also identified both the Swanson, Nolan, and Pelham Questionnaire for ADHD (SNAP-IV)92 and the Connors Rating S…”
BackgroundInfluentialLam, K. S. L., & Aman, M. G. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0213-z · Cited by 793
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609
Self-citation
Cited by
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Self-citationTrofinetide for the treatment of Rett syndrome: a randomized phase 3 study
Neul, J. L., Percy, A. K., Benke, T. A., Berry-Kravis, E. M., Glaze, D. G., Marsh, E. D., Lin, T., Stankovic, S., Bishop, K. M., & Youakim, J. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02398-1 · Cited by 190
Self-citationOutcome Measures for Clinical Trials in Down Syndrome
Esbensen, A. J., Hooper, S. R., Fidler, D., Hartley, S. L., Edgin, J., d'Ardhuy, X. L., Capone, G., Conners, F. A., Mervis, C. B., Abbeduto, L., et al. (2017) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-122.3.247 · Cited by 153
Self-citationFragXis Study Group, Youssef, E. A., Berry-Kravis, E., Czech, C., Hagerman, R. J., Hessl, D., Wong, C. Y., Rabbia, M., Deptula, D., John, A., et al. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.177 · Cited by 133
Self-citationTherapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
Self-citationBerry-Kravis, E., Horrigan, J. P., Tartaglia, N., Hagerman, R., Kolevzon, A., Erickson, C. A., Hatti, S., Snape, M., Yaroshinsky, A., Stoms, G., et al. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.04.019 · Cited by 102
Self-citationEffect of lovastatin on behavior in children and adults with fragile X syndrome: An open‐label study
Çaku, A., Pellerin, D., Bouvier, P., Riou, E., & Corbin, F. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36750 · Cited by 77
“Further research is warranted to identify more objective outcome measures as was suggested recently [Berry-Kravis et al., 2013].”
BackgroundOxytocin: Parallel Processing in the Social Brain?
Dölen, G. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12284 · Cited by 65
Cholesterol levels in Fragile X syndrome
Berry‐Kravis, E., Levin, R., Shah, H., Mathur, S., Darnell, J. C., & Ouyang, B. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36850 · Cited by 59
“It has been challenging to find consistent biomarkers that could give readouts for treatment effects or predict those more likely to respond to treatment, yet such markers are badly needed [Berry-Kravis et al., 2013].”
BackgroundSelf-citationPlacebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis
Curie, A., Yang, K., Kirsch, I., Gollub, R. L., des Portes, V., Kaptchuk, T. J., & Jensen, K. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133316 · Cited by 43
“Future work is necessary (as suggested by the recent meeting convened by the National Institutes of Health, Washington DC, 2012) in order to identify reliable and sensitive outcome measures for common use in clinical trials in FX [82] and more generally in ID patients.”
MethodLanguage Development in Individuals With Intellectual and Developmental Disabilities
(2016) · International Review of Research in Developmental Disabilities · doi:10.1016/bs.irrdd.2016.05.006 · Cited by 43
Self-citationNew insights of altered lipid profile in Fragile X Syndrome
Çaku, A., Seidah, N. G., Lortie, A., Gagné, N., Perron, P., Dubé, J., & Corbin, F. (2017) · PLOS ONE · doi:10.1371/journal.pone.0174301 · Cited by 36
D’Incal, C., Broos, J., Torfs, T., Kooy, R. F., & Vanden Berghe, W. (2022) · Cells · doi:10.3390/cells11081325 · Cited by 29
“For this reason, abnormalities in protein kinases and phosphorylation are thought to be involved in the molecular pathophysiology underlying the FXS [30,61].”
BackgroundNormal Performance of Fmr1 Mice on a Touchscreen Delayed Nonmatching to Position Working Memory Task
Leach, P. T., Hayes, J., Pride, M., Silverman, J. L., & Crawley, J. N. (2016) · eneuro · doi:10.1523/eneuro.0143-15.2016 · Cited by 27
“…been successfully used in subjects with intellectual disability (Green et al., 2009; van Nieuwpoort et al., 2011) including FXS (Van der Molen et al., 2010; Berry-Kravis et al., 2013); and (2) to identify cognitive deficits in tasks that include the capacity to increase demands on working memory.”
Method
Metadata
- Authors
- Berry-Kravis, E., Hessl, D., Abbeduto, L., Reiss, A. L., Beckel-Mitchener, A., & Urv, T. K.
- Venue
- Journal of Developmental & Behavioral Pediatrics
- Published
- 2013-09
- Volume
- 34
- Issue
- 7
- Pages
- 508-522
- ISSN
- 0196-206X (ISSN-L)
- OpenAlex
- W2044352563
- Cited by
- 154
- References
- 34
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.